U.K. – Digital pathology leaders Gestalt and Paige have joined forces to integrate Paige’s state-of-the-art AI applications into Gestalt’s PathFlow platform.
This strategic partnership aims to enhance diagnostic accuracy and streamline workflows for pathologists, ultimately contributing to improved patient outcomes.
Gestalt’s PathFlow platform, known for its versatile applications in primary diagnosis, education, and research, will now include Paige’s advanced AI algorithms.
This collaboration allows PathFlow users to seamlessly access AI-powered diagnostic tools, creating a unified workflow that improves efficiency and reduces diagnostic time.
Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt, highlighted the purpose behind the partnership, saying, “By partnering with Paige to include their AI applications in PathFlow, we are reinforcing our commitment to providing pathologists with the best tools available.
“This partnership underscores our dedication to enhancing the pathologist’s experience and ensuring the highest standards of patient care.”
Streamlined workflows for greater diagnostic confidence
The integration of Paige’s AI within PathFlow creates a streamlined workflow environment that enables pathologists to access multiple diagnostic tools on a single platform.
This efficiency supports quicker, more confident diagnoses, critical in cancer detection and other pathology use cases.
By consolidating diagnostic resources, PathFlow users experience a smoother, more efficient workflow that reduces time-to-diagnosis and enhances the overall quality of patient care.
Peter Hamilton, General Manager for Diagnostics at Paige, emphasized the benefits of this unified approach: “Leveraging Paige’s AI-powered applications, PathFlow users can experience an enhanced workflow that supports efficient case review, accelerates time to diagnosis, and allows for a more comprehensive approach to cancer detection, enabling pathologists to focus on what matters most—delivering precise and actionable insights for patient care.”
With all of Paige’s AI applications now available on PathFlow, the platform’s expanded capabilities offer robust support across a wide array of pathology cases, from primary diagnosis to specialized cancer detection.
This flexibility benefits both current and future users of PathFlow, enabling comprehensive diagnostic support across diverse pathology workflows.
Partnership highlights
